ArticleDiscover oncology2025
Quantitative assessment of the associations between MTR and MTRR gene polymorphisms and glioma risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposePrevious research on the correlation between methionine synthase (MTR) and methionine synthase reductase (MTRR) gene polymorphisms and the susceptibility to glioma has yielded varied results. This study aims to elucidate the potential impact of MTR and MTRR polymorphisms as contributing factors in the development of glioma. PATIENTS AND
methodsA comprehensive review of the relevant literature was conducted across several major databases, encompassing records from their inception through April 2025. The data were then synthesized using meta-analysis techniques.
resultsNo significant associations between the MTR rs1805087 polymorphism and glioma risk were identified under any genetic model across all populations (all p > 0.05). However, we found that MTRR rs1801394 polymorphism was significantly associated with the glioma risk for Asian population (all p < 0.05).
conclusionIn conclusion, our study indicates that the MTRR rs1801394 polymorphism serves as a protective factor in India populations but does not affect glioma risk in Caucasian population and Chinese population, which can be used as biomarkers for predicting glioma risk and can serve as targets for personalized treatments of glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.